Edition:
United Kingdom

Stellar Biotechnologies Inc (SBOT.OQ)

SBOT.OQ on NASDAQ Stock Exchange Capital Market

1.37USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$1.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
152,004
52-wk High
$10.08
52-wk Low
$1.33

Chart for

About

Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-target... (more)
No analyst recommendations are available for .

Overall

Beta: 2.30
Market Cap(Mil.): $15.16
Shares Outstanding(Mil.): 10.52
Dividend: --
Yield (%): --

Financials

  SBOT.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.43 -- --
ROI: -32.77 1.79 14.61
ROE: -33.17 3.28 16.33

Cryptocurrency firm Stellar gets Islamic finance certification

SYDNEY California-based Stellar has received certification from Islamic scholars for its blockchain platform and related cryptocurrency, aiming to integrate the technology into the field of sharia-compliant financial products.

17 Jul 2018

Cryptocurrency firm Stellar gets Islamic finance certification

SYDNEY, July 17 California-based Stellar has received certification from Islamic scholars for its blockchain platform and related cryptocurrency, aiming to integrate the technology into the field of sharia-compliant financial products.

17 Jul 2018

BRIEF-Stellar Acquisition Reduces Extension Date Of Initial Business Combination To August 24

* STELLAR ACQUISITION III INC. ANNOUNCES INCREASE IN MONTHLY CONTRIBUTION AMOUNT TO TRUST ACCOUNT POST-EXTENSION APPROVAL AND SHORTENING OF EXTENSION DATE TO AUGUST 24, 2018 Source text for Eikon: Further company coverage:

14 May 2018

BRIEF-Stellar Biotechnologies Announces Pricing Of $5.5 Mln Public Offering

* STELLAR BIOTECHNOLOGIES ANNOUNCES PRICING OF $5.5 MILLION PUBLIC OFFERING

11 May 2018

BRIEF-Stellar Biotechnologies Reports Q2 Loss Per Share Of $0.90

* STELLAR BIOTECHNOLOGIES REPORTS SECOND QUARTER FINANCIAL RESULTS

07 May 2018

BRIEF-Stellar Biotechnologies Announces One-For-Seven Reverse Split

* STELLAR BIOTECHNOLOGIES ANNOUNCES ONE-FOR-SEVEN REVERSE SPLIT

27 Apr 2018

Earnings vs. Estimates

No consensus analysis data available.